A phase I trial intended to target mTOR— and which involved metastatic metaplastic breast cancer treated with liposomal doxorubicin (D) and bevacizumab (A), with either temsirolimus (T) or everolimus (E) (DAT/DAE)—revealed that patients with advanced metaplastic breast cancer treated with mTOR-based systemic therapy had better long-term outcomes than those with nonmetaplastic TNBC, indicating that metaplastic histology may benefit from drugs targeting the PI3K/Akt/mTOR pathway [259]. This evidence concerns the gene MTOR and breast carcinoma.